Key result
Bioabsorbable polymer-coated everolimus-eluting stents demonstrated more stable early vascular healing with significantly lower rates of intra-stent thrombus at 4 months (8.3%) compared to bioresorbable vascular scaffolds (100%).
Why the study?
Recent clinical trials raised concerns regarding BVS safety and efficacy, and differences in vascular healing between BP-EES and BVS remained unclear.
Does bioresorbable vascular scaffolds (BVS) compared to bioabsorbable polymer-coated everolimus-eluting stents (BP-EES) improve vascular healing in patients with multivessel coronary artery disease?
Observational (n=13)
Open-label
No
Does bioresorbable vascular scaffolds (BVS) compared to bioabsorbable polymer-coated everolimus-eluting stents (BP-EES) improve vascular healing in patients with multivessel coronary artery disease?
In a within-patient comparison, bioresorbable vascular scaffolds demonstrated incomplete vascular healing and higher rates of intra-stent thrombus up to 12 months compared to bioabsorbable polymer-coated everolimus-eluting stents.
BVS associated with impaired healing; hypothesis-generating and should not yet change stent selection in multivessel disease.
Recent clinical trials have raised concerns about the safety and efficacy of ABSORB™ bioresorbable vascular scaffolds (BVS). The difference in the vascular healing process between SYNERGY™ bioabsorbable polymer-coated everolimus-eluting stents (BP-EES) and BVS remains unclear. The aim of the ENHANCE study was to compare vascular healing on BP-EES versus BVS by optical coherence tomography (OCT) and coronary angioscopy (CAS) at 4- and 12-month follow-ups. This is a prospective, non-randomized, single center clinical trial. Thirteen eligible patients with multivessel disease were enrolled. BP-EES and BVS were simultaneously implanted in the same patients, but in different coronary vessels. Imaging follow-up with both OCT and CAS was completed in 11 patients at 12 months. Neointimal coverage rates were similar between the two groups based on OCT measurements. The neointimal thickness of BP-EES was significantly thicker at the 12th month than at the 4th month, whereas the neointimal thickness of BVS did not change between the measurements taken at the 4th and 12th month. Existence of intra-stent thrombus was significantly higher in the BVS group, compared to the BP-EES group. On the other hand, CAS revealed that red-thrombi and yellow-plaque were more frequently observed in BVS at 4 months and up to 12-month follow-ups than in BP-EES. These findings suggested that the evidence of instability remained up to 12 months in the vascular healing with BVS, compared to that with BP-EES. Vascular healing of the stented wall was recognized at the very early phase after BP-EES implantation. However, vascular healing with BVS was still incomplete after 12 months.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2019) conducted an observational in Multivessel coronary artery disease (n=13). Bioabsorbable polymer-coated everolimus-eluting stents (BP-EES) vs. Bioresorbable vascular scaffolds (BVS) was evaluated on Intra-stent thrombus at 4 months by OCT (p=<0.001). Bioabsorbable polymer-coated everolimus-eluting stents demonstrated more stable early vascular healing with significantly lower rates of intra-stent thrombus at 4 months (8.3%) compared to bioresorbable vascular scaffolds (100%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: